In fact, HSP90α (also known as HSP86), in both structural (via tumor‐derived extracellular vesicles, [TEVs]) and soluble forms (via TLR4 signaling), also plays a key role in suppressing anti‐tumor immunity in melanoma by promoting the development of MDSCs.28, 29. Here, TLR4 is linked to melanoma.